Xiaomei Jin

Xiaomei Jin has extensive work experience in the pharmaceutical industry. Xiaomei started their career as an Associate Principal Investigator at Canji Inc., where they led a team focusing on antiangiogenic cancer gene therapy and made significant contributions to the discovery and development of new drugs and gene therapy vectors. Xiaomei also published papers and presented at international conferences during their time there. Xiaomei then joined GenWaybio, Inc. as a Group Leader, where they led various projects related to hybridoma development, monoclonal antibody production, gene expression and protein production, and ELISA kit development. After that, they worked at Nitto Denko Technical as a Director, managing a team and leading the discovery and development of siRNA drugs against liver fibrosis. During this time, they also invented new approaches for drug screening and validation. Xiaomei then joined Biogen Idec as a Clinical Scientist, where they analyzed clinical trial data, managed publication planning, and provided responses to medical and scientific inquiries for study drugs. Their most recent role was at Cubist Pharmaceuticals, where they served as a Senior Clinical Research Scientist, working on pediatric trials of Cubicin. Xiaomei contributed to clinical study design, execution, and monitoring, authored clinical study documents, and presented at internal and external trainings. Overall, Xiaomei has a strong background in clinical research and drug development, with expertise in various areas of pharmaceutical science.

Xiaomei Jin holds a Doctor of Philosophy (Ph.D.) degree from the University of Texas Health Science Center at Houston, Graduate School of Biomedical Sciences. The field of study for their Ph.D. is Biochemistry and Molecular Biology. No specific information regarding the start and end years of their education is available.